Analytical Data
-
Gene name
KRT33A
- Application
-
Alternative Names
KRTHA3A; Ha-3I; Krt1-3; K33A; HHA3-I; HKA3A; Keratin,Hair,Acidic 3A; Hard Keratin Type I 3I; Keratin, type I cuticular Ha3-I
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O76009
-
Expression Region
Lys57~Glu363
-
Molecular Weight
50kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KRT33A, a member of the keratin gene family, is primarily expressed in the epithelial tissues and plays a crucial role in the structural integrity and function of hair and skin. Keratins are essential intermediate filament proteins that contribute to the formation of the cytoskeleton in epithelial cells, providing mechanical resilience and protection. The study of KRT33A and its recombined forms is significant due to its potential implications in understanding various dermatological conditions and hair disorders. Research has shown that mutations or dysregulation of keratin genes, including KRT33A, can lead to a range of keratinopathies, which are characterized by abnormal keratinocyte differentiation and disrupted skin barrier functions. Moreover, KRT33A's involvement in the hair follicle cycle suggests that it may play a role in hair growth and loss mechanisms. As such, recombinant forms of KRT33A are being explored for their utility in therapeutic applications, including gene therapy, regenerative medicine, and cosmetic products aimed at enhancing hair and skin health. Understanding the functional properties of KRT33A through recombinant protein studies may provide insight into novel treatment strategies for keratin-related disorders and could lead to advancements in regenerative treatments involving skin and hair follicles. Consequently, KRT33A serves not only as a critical structural component within epithelial tissues but also as a valuable target for future research aimed at developing innovative therapeutic solutions.
